BEAM-201 (NCT05885464) is an allogeneic, CD7-directed CAR-T cell therapy developed for treating CD7-positive T-cell malignancies such as T-cell acute lymphoblastic leukemia (T-ALL). The gene discussed is CD7; the disease is T-cell acute lymphoblastic leukemia.